跳至主要内容
临床试验/NCT06194747
NCT06194747招募中不适用

Quality Improvement in Time to Treatment of Status Epilepticus

Nationwide Children's Hospital1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2024年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
450
试验地点
1
主要终点
Time from the SE diagnosis to first dose of BZD

研究概览

简要总结

This is a stepped-wedge cluster randomized effectiveness-implementation hybrid study aimed at determining the effect of dissemination of a QI bundle on the time to treatment of SE among hospitalized, non-critically ill children. The primary study endpoint is to decrease the time from the SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality.

详细描述

The overall study design is a stepped-wedge cluster randomized trial. A stepped-wedge is a unidirectional crossover design in which clusters switch treatments at different time points, enabling statistically rigorous assessment of interventions while reducing ethical and resource limitations for quality improvement studies.[1] Seven centers will be randomly assigned to implement the QI bundle at staggered 1-month intervals after a baseline period. Only the timing of the dissemination visit will be randomized; all sites will receive the same materials and perform the same activities (e.g. focus group, process map development, simulations).

This study is an effectiveness-implementation hybrid study. The effectiveness-implementation hybrid design is ideal for assessing both clinical interventions and implementation.17 Importantly, our interventions have strong face-validity, are evidence-based, low-risk and low-cost. For instance, the price to change BZD formulations is nominal (~$1 per dose), and other QI bundle interventions are primarily focused on frontline staff process changes. While testing the effect of the QI bundle on time to BZD treatment, we will utilize this framework and mixed methods analysis to measure implementation and identify barriers and facilitators. Thus, this proposal is of high-value, as it will provide randomized multicenter efficacy data while providing understanding for broad implementation following study end.

For the effectiveness component, we will utilize a stepped-wedge cluster randomized design. Based on our preliminary data, the intraclass correlation coefficient is estimated around 0.5, an overall sample size of 60 episodes will be adequate to achieve powers greater than 90%. A potential pitfall of the stepped wedge design is the potential confounding effects of temporal trends. We will mitigate this by tracking data at the primary site, which will be in the sustain phase throughout the study entirety. We reduce temporal effects of site enrollment (e.g., staffing changes, temporal trends in hospital admissions) by enrolling sites at different times throughout the calendar year.

The implementation component was designed utilizing the Practical, Robust Implementation and Sustainability Model (PRISM).[2] PRISM provides a scientifically rigorous and structured approach to implementation strategy development through domains focusing on (1) program, (2) external environment, (3) implementation and sustainability infrastructure and (4) recipients.[2] These elements are addressed as follows:

Program. Organizational readiness across the study sites will be critical for success. Our proposal is based on evidence derived from a successful single-center study. The QI bundle is low-cost and all interventions are currently FDA-approved. Our innovative de-implementation of time-consuming, low-value workflows (e.g. IV medication administration) will decrease care complexity in the initial stages of SE treatment. The QI bundle components are trialable, adaptable and reversible. Treatment results are immediately observable by stakeholders through individual outcomes (SE cessation) and shared measure and feedback data reports. We highlight improved outcomes and safety as organizational, caregiver, and patient priorities to achieve broad buy-in.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Participants will be masked as to whether the implementation bundle has been dissemination or implemented within the site they receive treatment.

入排标准

年龄范围
30 Days 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • SE episode occurs in a male or female child aged between > 30 days to < 19 years
  • Seizures meeting AT LEAST ONE of the following criteria:
  • continuous clinically apparent seizure lasting greater than 5 minutes
  • continuous clinically apparent seizure of any duration receiving BZD
  • repeated seizures without return to neurological baseline within 5 minutes

排除标准

  • SE episode occurs in a child with infantile spasms
  • SE episode occurs in a child with electrographic-only seizures without clinical signs other than encephalopathy

结局指标

主要结局

Time from the SE diagnosis to first dose of BZD

时间窗: 30 days

Time in minutes from SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality

次要结局

  • Cost of hospitalization(30 days)
  • ICU transfer rate(30 days)
  • Change in PCPC score(30 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Improving Status Epilepticus Treatment Times | 临床试验